Hematopoietic progenitor cells, cord (hpc-c) - Biologic Drug Details

Summary for hematopoietic progenitor cells, cord (hpc-c)

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hematopoietic progenitor cells, cord (hpc-c) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hematopoietic progenitor cells, cord (hpc-c) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for hematopoietic progenitor cells, cord (hpc-c) Derived from Patent Text Search

No patents found based on company disclosures

Hematopoietic progenitor cells, cord (hpc-c) Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Hematopoietic Progenitor Cells, Cord (HPC-C)

Introduction to HPC-C

Hematopoietic progenitor cells (HPCs) derived from umbilical cord blood are a crucial component in the field of stem cell therapy and transplantation. These cells have the potential to treat a variety of diseases, including blood-related cancers, autoimmune diseases, and genetic disorders.

Market Size and Growth

The market for cord stem cell banking, which includes HPC-C, is experiencing significant growth. As of 2022, the global cord stem cell banking market was valued at USD 9.3 billion and is projected to reach USD 45.64 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 22% during the forecast period from 2023 to 2030[1].

Drivers of Market Growth

Increasing Demand for Cord Blood and Tissue Storage

The integration of cord blood and tissue storage with genetic testing services is a key driver of market growth. This combination enhances the product portfolio for existing clients and attracts new customers. For instance, companies like Natera have launched services that enable expectant parents to collect, store, and retrieve cord blood and tissue for future medicinal use[1].

Rising Incidence of Cancer and Chronic Diseases

The increasing number of cancer patients and individuals with chronic diseases is another significant factor. Stem cell transplants, particularly those using HPC-C, are effective treatments for conditions such as multiple myeloma and leukemia. The growing awareness and adoption of these treatments in regions like North America and the Asia-Pacific are driving market expansion[1][4].

Advancements in Technology

Technological advancements, including gene-editing technologies like CRISPR, are enhancing the precision and potential of stem cell therapies. These innovations are making HPC-C more viable for treating genetic disorders and other complex conditions, thereby boosting market demand[3].

Geographical Market Dynamics

North America

North America dominates the cord stem cell banking market due to the presence of major market players in the U.S., ongoing approvals of stem cell lines for disease treatment, and growing public awareness. The region's advanced healthcare infrastructure and regulatory support also contribute to its leading position[1].

Asia-Pacific

The Asia-Pacific region is expected to witness significant growth due to an aging population, an increase in chronic diseases, and rising healthcare expenditure. The development of healthcare infrastructure and supportive regulatory frameworks in countries like China are further driving the market in this region[1][3].

Europe

Europe is also experiencing growth, driven by the increasing adoption of stem cell storage services and the use of these cells in regenerative and transplant medicine. Companies in Europe are offering additional services such as genetic testing, which is contributing to the market's expansion[4].

Clinical Applications and Emerging Therapies

Transplant Medicine

HPC-C are widely used in hematopoietic stem cell transplants, which are crucial for treating blood-related cancers and other hematological disorders. As of December 2018, over 500 cord blood units had been released for clinical applications, with a significant portion used in hematopoietic stem cell transplants[2].

Regenerative Medicine

These cells are also being explored in regenerative medicine for their potential to repair damaged tissues and organs. Emerging advanced cellular therapies, including the use of induced pluripotent stem cells (iPSCs), natural killer cells (NK cells), and chimeric antigen receptor T cells (CAR-T cells), are expanding the therapeutic applications of HPC-C[2].

Neurology, Cardiology, and Autoimmune Diseases

Stem cell therapies, including those using HPC-C, are being investigated for their potential in treating neurological, cardiovascular, and autoimmune diseases. This broadening of therapeutic areas is expected to further increase the demand for HPC-C[3].

Ethical and Regulatory Considerations

The market for HPC-C is influenced by ethical and regulatory challenges. The complexity of stem cell treatments requires careful navigation of ethical guidelines and regulatory requirements. However, as regulatory bodies become more receptive to approving new stem cell-based treatments, the market is expected to grow more rapidly[3].

Financial Trajectory

Current Market Value

The global stem cell umbilical cord blood market was valued at USD 4.9 billion in 2022. This market is projected to reach USD 19.4 billion by 2031, growing at a CAGR of 16.5% during the forecast period from 2023 to 2031[4].

Future Projections

The broader stem cell therapy market, which includes HPC-C, is expected to grow from USD 14.15 billion in 2023 to USD 48.89 billion by 2033, with a CAGR of 13.2% from 2024 to 2033. The U.S. market alone is projected to be worth around USD 17.70 billion by 2033, with a CAGR of 12.79% during the same period[3].

Key Takeaways

• The cord stem cell banking market, including HPC-C, is experiencing rapid growth driven by increasing demand for cord blood and tissue storage, rising incidence of cancer and chronic diseases, and technological advancements.
• North America and the Asia-Pacific region are key markets, with Europe also showing significant growth.
• HPC-C are crucial in transplant medicine and are being explored in regenerative medicine and other therapeutic areas.
• Ethical and regulatory considerations are important factors influencing market growth.
• The financial trajectory indicates a substantial increase in market value over the next decade.

FAQs

What is the current market size of the cord stem cell banking market?

The global cord stem cell banking market was valued at USD 9.3 billion in 2022[1].

What is the projected growth rate of the cord stem cell banking market?

The market is expected to grow at a CAGR of 22% from 2023 to 2030[1].

Which regions are driving the growth of the HPC-C market?

North America, the Asia-Pacific, and Europe are the key regions driving market growth[1][3][4].

What are the main clinical applications of HPC-C?

HPC-C are primarily used in hematopoietic stem cell transplants and are being explored in regenerative medicine and other therapeutic areas such as neurology, cardiology, and autoimmune diseases[2][3].

What are the ethical and regulatory challenges facing the HPC-C market?

The market faces ethical and regulatory challenges due to the complexity of stem cell treatments, requiring careful navigation of ethical guidelines and regulatory requirements[3].

Sources

1. Data Bridge Market Research: "Cord Stem Cell Banking Market Scope & Segmentations - 2030"
2. MDPI: "The Future State of Newborn Stem Cell Banking"
3. Biospace: "Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033"
4. Straits Research: "Stem Cell Umbilical Cord Blood Market Share, Demand, Report to 2031"